Monday 23 September 2019 ,
Monday 23 September 2019 ,
Latest News
  • 5 JMB men jailed in Aug 17 bomb attack case
  • UK announces extra £87 mn funding for Rohingya crisis
  • DNCC launches drive to free roads, footpaths
  • Trump to join Indian-American extravaganza in Modi bromance
  • Rifat murder: Minni meets lawyer in Dhaka
3 June, 2019 00:00 00 AM

Aspirin 'safe' for brain-bleed strokes

FDA
Aspirin 'safe' for brain-bleed strokes

Recently, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

The FDA also approved the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit, to detect the PIK3CA mutation in a tissue and/or a liquid biopsy. Patients who are negative by the therascreen test using the liquid biopsy should undergo tumor biopsy for PIK3CA mutation testing.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient’s specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks.”

Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body (most often the bones, lungs, liver or brain). When breast cancer is hormone-receptor positive, patients may be treated with anti-hormonal treatment (also called endocrine therapy), alone or in combination with other medicines, or chemotherapy.

The efficacy of Piqray was studied in the SOLAR-1 trial, a randomized trial of 572 postmenopausal women and men with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed while on or after receiving an aromatase inhibitor. Results from the trial showed the addition of Piqray to fulvestrant significantly prolonged progression- free survival (median of 11 months vs. 5.7 months) in patients whose tumors had a PIK3CA mutation.

Common side effects of Piqray are high blood sugar levels, increase in creatinine, diarrhea, rash, decrease in lymphocyte count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in lipase (enzymes released by the pancreas), decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, aPTT prolonged (blood clotting taking longer to occur than it should), and hair loss.

Health care professionals are advised to monitor patients taking Piqray for severe hypersensitivity reactions (intolerance). Patients are warned of potentially severe skin reactions (rashes that may result in peeling and blistering of skin or mucous membranes like the lips and gums). Health care professionals are advised not to initiate treatment in patients with a history of severe skin reactions such as Stevens-Johnson Syndrome, erythema multiforme, or toxic epidermal necrolysis.

Patients on Piqray have reported severe hyperglycemia (high blood sugar), and the safety of Piqray in patients with Type 1 or uncontrolled Type 2 diabetes has not been established. Before initiating treatment with Piqray, health care professionals are advised to check fasting glucose and HbA1c, and to optimize glycemic control. Patients should be monitored for pneumonitis/interstitial lung disease (inflammation of lung tissue) and diarrhea during treatment. Piqray must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

In Bangladesh, snake bite is common especially in rainy season with incidence density one of the highest in the world, which is around 623.4/100,000 persons…
Snakes and snake bites

Snakes and snake bites

Introduction I have spent long 14 years in Africa including 2 years in East Africa and 12 years in North Africa and have experience of seeing and treating…
NCDC guideline: Management of snakebite in Bangladesh

NCDC guideline: Management of snakebite in Bangladesh

Snakes and snakebites have been known to the people of Bangladesh since ancient time. Snakebite results most often from an unfortunate accidental interaction…
Prevalence of snakebite envenoming

Prevalence of snakebite envenoming

One of the consequences of inadequate efforts to control snakebite envenoming in the past is that the available epidemiological data are fragmented and…
Why are so many people still dying from snake bites?

Why are so many people still dying from snake bites?

DR NICK CASEWELL & DR STUART AINSWORTH   Tens of thousands of people die from snake bites worldwide every year. Lack of treatment and even the…
What you should know about chronic pain

What you should know about chronic pain

Pain. It’s a small, four-letter word that can occupy such a huge part of some people’s lives. The country asks for a month of awareness and…
What is the anti-inflammatory diet?

What is the anti-inflammatory diet?

AMANDA CAPRITTO The anti-inflammatory diet is based on a pretty sound and simple claim: Chronic inflammation leads to chronic disease, and reducing inflammation…
Sudden cardiac deaths can be prevented with advanced cardiac devices

Sudden cardiac deaths can be prevented with advanced cardiac devices

September 2019, Majority of public can’t differentiate between a heart attack and sudden cardiac arrest. Heart Attack is a blood circulation problem…
Common cold stopped by experimental approach

Common cold stopped by experimental approach

JAMES GALLAGHER  Scientists think they have found a way to stop the common cold and closely related viruses which can cause paralysis. Instead of…
FDA approves Rinvoq (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis

FDA approves Rinvoq (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis

AbbVie, a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib),…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting